Azimine. VI. 1-Alkoxycarbony 1-2,3-dialkyl- und -2,3-diaryl-azimine

Azimines VI: 1-Alkoxycarbonyl-2,3-dialkyl- and -2,3-diarylazimines Alkoxycarbonyl-nitrenes 2 – generated in situ by α-elimination from N-[(4-nitrophenyl)-sulfonyloxy]carbamates 4 – were reacted with six aliphatic and aromatic azo compounds to yield 1-alkoxycarbonyl-azimines 11 (R′ = Alkyl). Thus, (2Z)- or (2E)- 1 -alkoxycarbonyl-2,3-diisopropyl-azimines ( 8 or 9 ) were obtained stereospecifically from (E)- or (Z)-1,1′-dimethylazoethane ( 5 or 6 ) and 1-alkoxycarbonyl -2,3-(cis-1,3-cyclopentylene)-azimines ( 10 ) resulted from 2,3-diazabicyclo[2.2.1]-2-heptene ( 7 ), always using both ethoxy- and methoxycarbonyl-nitrene ( 2a and 2b ). With 2a , (E)-azobenzene ( 14 ) was converted only to a single stereoisomer of 1-ethoxycarbonyl-2,3-diphenyl-azimine ( 17 ) and both stereoisomers of azo(p-toluene) ( 15 or 16 ) reacted to give the same stereoisomer of 1-ethoxycarbonyl-2,3-di(p-tolyl)-azimine ( 18 ).     

Purinenucleoside analogs. 2. 9-(1-Alkoxyethyl-1)-6-substituted purines

Vinyl ethers react with 6-chloro- and 6-methylthiopurines in acid medium to give 9-(1-alkoxyethyl-1)-6-chloro- and 6-methylthiopurines. The 6-chloro compounds were used to prepare 9-(1-alkoxyethyl-1)-6-mercaptopurines. All the synthesized compounds proved to be inactive against lympholeucosis P 388, and Lewis carcinona grafted under kidney capsules in mice.For Communication 1, see [1].Translated from Khimiya Geterotsiklicheskikh Soedinenii, No. 3, pp. 403–406, March, 1986.     

3-Bromo-2-(tert-butylsulfonyl)-1-propene. A multi-coupling reagent Part 1.

3-Bromo-2-(tert-butylsulfonyl)-1-propene $\text{4}$ is easily available in two steps from allyl-tert-butylthioether $\text{5}$ (70% overall yield). It reacts with a great variety of carbanions to give functionnalized α, β-unsaturated sulfones of type $\text{7}$ in high yields. A second nucleophile (lithium cuprates) can then be added to compounds $\text{7}$ to furnish functionnalized sulfones of type $\text{3}$ (Y=SO₂-tert-butyl).     

3-Bromo-2-(tert-butylsulfonyl)-1-propene. A multi-coupling reagent. Part 2. <1

3-bromo-2-(tert-butylsulfonyl)-1-propene 1 reacts in good yields with various electrophiles (aldehydes, ketones, nitriles and alkynes) in the presence of zinc metal to give unsaturated sulfones of type 4. These compounds can further react with soft or hard nucleophiles (alkyl-, vinyl-, aryllithium compounds, a nitroparaffin or dimethylmalonate) to yield highly functionnalized sulfones of type 5 which can be readily transformed into enones or into a dienone. Thus sulfone 1 is a versatile multi-coupling reagent which is synthetically equivalent to the $\text{a}{}^2\text{a}{}^{\mathrm{2\prime }}$ synthon 8 and to the $\text{d}{}^2\text{d}{}^{\mathrm{2\prime }}$ synthons 9 and 10.     

Bridged cyanine dyes. Part 1. 1-(N-methyl-4-pyridinio)-3-(N-methylpyridylene)cyclopenta-1,4-dienes

1,3-Bis(N-methyl-4-pyridinio)propane is condensed with a series of α-diketones to form deep red monocyanine dyes 8 . In strongly acidic solutions C-protonation occurs at the central carbon atom. A similar condensation with α-ketoesters yields zwitterionic cyanines 12 with extinction coefficients exceeding 10⁵.     

Optically active antifungal azoles. XIII. Synthesis of stereoisomers and metabolites of 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone (TAK-456)

1-[(1R,2R)-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone [(1R,2R)-1: TAK-456] is a new antifungal agent selected as a candidate for clinical trials. The three stereoisomers [(1S,2R)-, (1S,2S)- and (1R,2S)-1] of this compound were prepared as authentic samples to determine the enantiomeric and diastereomeric purity of TAK-456 as well as to compare their in vitro antifungal activity. Pharmacokinetic studies of TAK-456 using rats identified the existence of metabolites in the liver homogenate. The structures of the major metabolites were assigned as 4-hydroxy-2-imidazolidinone (3) and/or 5-hydroxy-2-imidazolidinone (4), based on HPLC and LC/MS/MS analyses. These hydroxylated compounds, 3 and 4, were prepared by reduction of the corresponding imidazolidinediones, 11 and 12, and confirmed to be identical to the metabolites by HPLC. In vitro antifungal activities of the three stereoisomers and the synthesized metabolites were considerably weaker than TAK-456.